Epigenica has been awarded a Proof-of-Concept grant of €150,000 to begin commercialization of a new platform technology. The ERC PoC hmqPro will focus on developing novel highly-multiplexed, quantitative biomarker profiling.
Epigenica has been awarded a Proof-of-Concept grant of €150,000 to begin commercialization of a new platform technology. The ERC PoC hmqPro will focus on developing novel highly-multiplexed, quantitative biomarker profiling.
Epigenica has through its optimization of the technology discovered another strong patentable technology which is currently under drafting together with our IP partners.
Epigenica News: Epigenica receives grant from ALMI innovation ALMI Innovation has provided seed funding for Epigenica to develop our IP portfolio. © 2021 All rights
This website uses cookies. By continuing to use this site, you accept our use of cookies.
